Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amlycure D.S. is a high-strength Ayurvedic polyherbal formulation developed by Aimil Pharmaceuticals for the management of various liver disorders and the promotion of hepatic health. Available in capsule and syrup forms, the capsule variant contains a concentrated blend of herbal extracts including *Picrorhiza kurroa* (Kutaki), *Andrographis paniculata* (Kalmegh), *Boerhavia diffusa* (Punernava), and *Phyllanthus niruri* (Bhuiamla). The formulation is designed to act as a hepatoprotective and hepatostimulative agent, working at the cellular level to maintain hepatocyte integrity, normalize liver enzymes (LFT parameters), and support detoxification. It is clinically indicated for conditions such as fatty liver (steatosis), alcohol-induced liver damage, drug-induced hepatotoxicity, and digestive complaints like indigestion and loss of appetite.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Amlycure D.S..